Amundi Asset Management US
ONCE

Amundi Asset Management US’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Amundi Asset Management US’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-81,200
Closed -$6.72M – 1671
2018
Q2 		$6.72M Sell
81,200
-37,300
-31% -$2.88M 0.01% 838
2018
Q1 		$7.89M Buy
118,500
+33,400
+39% +$1.93M 0.01% 747
2017
Q4 		$4.38M Buy
85,100
+25,808
+44% +$1.85M 0.01% 867
2017
Q3 		$5.29M Buy
+59,292
New +$4.5M 0.02% 380

Other funds holding ONCE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Amundi Asset Management US's ONCE Position: Q3 2018 in Review

Amundi Asset Management US sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 81,200 shares — an estimated $6.72M sold.

Amundi Asset Management US first reported a position in ONCE in Q3 2017 and held it in 4 quarters. The position peaked at $7.89M in Q1 2018. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

  • Amundi Asset Management US reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 81,200 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $6.72M.
  • Amundi Asset Management US first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
  • Amundi Asset Management US's Spark Therapeutics, Inc. Common Stock position peaked at $7.89M in Q1 2018.
  • 176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Amundi Asset Management US's 13F filing for Q3 2018, filed 14 Nov 2018.